Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles

Journal of Controlled Release

Volumn 170, Issue 2, 2013, Pages 268-278

  Liu, Dongfei ^a   Bimbo, Luis M ^a   Mäkilä, Ermei ^b   Villanova, Francesca ^a   Kaasalainen, Martti ^a,c   Herranz Blanco, Barbara ^b   Caramella, Carla M ^c   Lehto, Vesa Pekka ^d   Salonen, Jarno ^b   Herzig, Karl Heinz ^e   Hirvonen, Jouni ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

Co delivery; Drug release; Indomethacin; Nanoparticles; Permeation; Porous silicon; PYY3 36

Indexed keywords

BIOACTIVITY; DRUG PRODUCTS; HYDROPHILICITY; HYDROPHOBICITY; MONOLAYERS; NANOPARTICLES; PEPTIDES; PERMEATION; SILICON;

CO DELIVERIES; CONFORMATIONAL ANALYSIS; DRUG RELEASE; DRUG-RELEASE BEHAVIOUR; HYDROPHOBIC AND HYDROPHILIC; INDOMETHACIN; NANOPARTICULATE DRUG DELIVERY SYSTEMS; PYY3-36;

POROUS SILICON;

INDOMETACIN; NANOCARRIER; PEPTIDE YY [3-36]; SILICON NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT; PEPTIDE YY; SILICON;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; COLON CARCINOMA; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROPHOBICITY; IN VITRO STUDY; INTESTINE CELL; NANOFABRICATION; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CACO 2 CELL LINE; CELL LINE; CELL SURVIVAL; CHEMICAL PHENOMENA; CHEMISTRY; COCULTURE; DRUG EFFECTS; HEPG2 CELL LINE; HT 29 CELL LINE; MOUSE; PERMEABILITY; POROSITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CACO-2 CELLS; CELL LINE; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG CARRIERS; HEP G2 CELLS; HT29 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOMETHACIN; MICE; NANOPARTICLES; PEPTIDE FRAGMENTS; PEPTIDE YY; PERMEABILITY; POROSITY; SILICON;

EID: 84879494517     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.05.036     Document Type: Article

References (67)

1. C.M. Hu, S. Aryal, L. Zhang, Nanoparticle-assisted combination therapies for effective cancer treatment, Ther. Deliv. 1 (2010) 323-334.
2. H.B. Zhang, G.J. Wang, H.A. Yang, Drug delivery systems for differential release in combination therapy, Expert Opin. Drug Deliv. 8 (2011) 171-190.
3. F. Kratz, A. Warnecke, Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems, J. Control. Release 164 (2012) 221-235.
4. H.A. Meng, M. Liong, T.A. Xia, Z.X. Li, Z.X. Ji, J.I. Zink, A.E. Nel, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-plycoprotein siRNA to overcome drug resistance in a cancer cell line, ACS Nano 4 (2010) 4539-4550.
5. S. Aryal, C.M. Hu, L. Zhang, Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy, Mol. Pharm. 8 (2011) 1401-1407.
6. Y. Wang, S.J. Gao, W.H. Ye, H.S. Yoon, Y.Y. Yang, Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable co-polymer, Nat. Mater. 5 (2006) 791-796. (Pubitemid 44570860)
7. M. Das, S.K. Sahoo, Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance, PLoS One 7 (2012).
8. Q. Liu, J.X. Zhang, W. Sun, Q.R.B. Xie, W.L. Xia, H.C. Gu, Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells, Int. J. Nanomedicine 7 (2012) 999-1013.
9. C.E. Soma, C. Dubernet, D. Bentolila, S. Benita, P. Couvreur, Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles, Biomaterials 21 (2000) 1-7.
10. Tennyson Doane, C. Burda, Nanoparticle mediated non-covalent drug delivery, Adv. Drug Deliv. Rev. (2012), http://dx.doi.org/10.1016/j.addr.2012. 05.012.
11. L.F. Zhang, A.F. Radovic-Moreno, F. Alexis, F.X. Gu, P.A. Basto, V. Bagalkot, S.Y. Jon, R.S. Langer, O.C. Farokhzad, Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates, ChemMedChem 2 (2007) 1268-1271.
12. S. Aryal, C.M.J. Hu, L.F. Zhang, Combinatorial drug conjugation enables nanoparticle dual-drug delivery, Small 6 (2010) 1442-1448.
13. N. Kolishetti, S. Dhar, P.M. Valencia, L.Q. Lin, R. Karnik, S.J. Lippard, R. Langer, O.C. Farokhzad, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy, Proc. Natl. Acad. Sci. U.S.A. 107 (2010) 17939-17944.
14. S. Sengupta, D. Eavarone, I. Capila, G.L. Zhao, N. Watson, T. Kiziltepe, R. Sasisekharan, Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system, Nature 436 (2005) 568-572. (Pubitemid 41112931)
15. F. Cui, K. Shi, L.Q. Zhang, A.J. Tao, Y. Kawashima, Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation, J. Control. Release 114 (2006) 242-250. (Pubitemid 44291843)
16. S. Deshayes, M. Morris, F. Heitz, G. Divita, Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy, Adv. Drug Deliv. Rev. 60 (2008) 537-547. (Pubitemid 351222678)
17. A.J. Almeida, E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins, Adv. Drug Deliv. Rev. 59 (2007) 478-490. (Pubitemid 47260710)
18. H.A. Santos, L.M. Bimbo, V.P. Lehto, A.J. Airaksinen, J. Salonen, J. Hirvonen, Multifunctional porous silicon for therapeutic drug delivery and imaging, Curr. Drug Discov. Technol. 8 (2011) 228-249.
19. E.J. Anglin, L.Y. Cheng, W.R. Freeman, M.J. Sailor, Porous silicon in drug delivery devices and materials, Adv. Drug Deliv. Rev. 60 (2008) 1266-1277.
20. E. Tasciotti, X.W. Liu, R. Bhavane, K. Plant, A.D. Leonard, B.K. Price, M.M.C. Cheng, P. Decuzzi, J.M. Tour, F. Robertson, M. Ferrari, Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications, Nat. Nanotechnol. 3 (2008) 151-157. (Pubitemid 351355132)
21. Hamsa Jaganathan, B. Godin, Biocompatibility assessment of Si-based nano- and micro-particles, Adv. Drug Deliv. Rev. 64 (2012) 1800-1819.
22. J.H. Park, L. Gu, G. von Maltzahn, E. Ruoslahti, S.N. Bhatia, M.J. Sailor, Biodegradable luminescent porous silicon nanoparticles for in vivo applications, Nat. Mater. 8 (2009) 331-336.
23. H.A. Santos, J. Hirvonen, Nanostructured porous silicon materials: potential candidates for improving drug delivery, Nanomedicine (Lond.) 7 (2012) 1281-1284.
24. A. Parodi, N. Quattrocchi, A.L. van de Ven, C. Chiappini, M. Evangelopoulos, J.O. Martinez, B.S. Brown, S.Z. Khaled, I.K. Yazdi, M.V. Enzo, L. Isenhart, M. Ferrari, E. Tasciotti, Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions, Nat. Nanotechnol. 8 (2013) 61-68.
25. D.M. Fan, E. De Rosa, M.B. Murphy, Y. Peng, C.A. Smid, C. Chiappini, X.W. Liu, P. Simmons, B.K. Weiner, M. Ferrari, E. Tasciotti, Mesoporous silicon-PLGA composite microspheres for the double controlled release of biomolecules for orthopedic tissue engineering, Adv. Funct. Mater. 22 (2012) 282-293.
26. M. Kovalainen, J. Monkare, E. Makila, J. Salonen, V.P. Lehto, K.H. Herzig, K. Jarvinen, Mesoporous silicon (PSi) for sustained peptide delivery: effect of PSi mi-croparticle surface chemistry on peptide YY3-36 release, Pharm. Res. 29 (2012) 837-846.
27. M. Kilpelainen, J. Monkare, M.A. Vlasova, J. Riikonen, V.P. Lehto, J. Salonen, K. Jarvinen, K.H. Herzig, Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery, Eur. J. Pharm. Biopharm. 77 (2011) 20-25.
28. T. Tanaka, L.S. Mangala, P.E. Vivas-Mejia, R. Nieves-Alicea, A.P. Mann, E. Mora, H.D. Han, M.M. Shahzad, X. Liu, R. Bhavane, J. Gu, J.R. Fakhoury, C. Chiappini, C. Lu, K. Matsuo, B. Godin, R.L. Stone, A.M. Nick, G. Lopez-Berestein, A.K. Sood, M. Ferrari, Sustained small interfering RNA delivery by mesoporous silicon particles, Cancer Res. 70 (2010) 3687-3696.
29. J.S. Andrew, E.J. Anglin, E.C. Wu, M.Y. Chen, L.Y. Cheng, W.R. Freeman, M.J. Sailor, Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide, Adv. Funct. Mater. 20 (2010) 4168-4174.
30. L.M. Bimbo, M. Sarparanta, H.A. Santos, A.J. Airaksinen, E. Makila, T. Laaksonen, L. Peltonen, V.P. Lehto, J. Hirvonen, J. Salonen, Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats, ACS Nano 4 (2010) 3023-3032.
31. 18F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography, Mol. Pharm. 8 (2011) 1799-1806.
32. M. Sarparanta, L.M. Bimbo, J. Rytkonen, E. Makila, T.J. Laaksonen, P. Laaksonen, M. Nyman, J. Salonen, M.B. Linder, J. Hirvonen, H.A. Santos, A.J. Airaksinen, Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution, Mol. Pharm. 9 (2012) 654-663.
33. M.P. Sarparanta, L.M. Bimbo, E.M. Makila, J.J. Salonen, P.H. Laaksonen, A.M.K. Helariutta, M.B. Linder, J.T. Hirvonen, T.J. Laaksonen, H.A. Santos, A.J. Airaksinen, The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems, Biomaterials 33 (2012) 3353-3362.
34. L.M. Bimbo, M. Sarparanta, E. Makila, T. Laaksonen, P. Laaksonen, J. Salonen, M.B. Linder, J. Hirvonen, A.J. Airaksinen, H.A. Santos, Cellular interactions of surface modified nanoporous silicon particles, Nanoscale 4 (2012) 3184-3192.
35. L.M. Bimbo, E. Makila, J. Raula, T. Laaksonen, P. Laaksonen, K. Strommer, E.I. Kauppinen, J. Salonen, M.B. Linder, J. Hirvonen, H.A. Santos, Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles, Biomaterials 32 (2011) 9089-9099.
36. D. Liu, E. Mäkilä, H. Zhang, B. Herranz, M. Kaasalainen, P. Kinnari, J. Salonen, J. Hirvonen, H.A. Santos, Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release, Adv. Funct. Mater. 23 (2013) 1893-1902.
37. J.R. Dorvee, M.J. Sailor, G.M. Miskelly, Digital microfluidics and delivery of molecular payloads with magnetic porous silicon chaperones, Dalton Trans. (2008) 721-730. (Pubitemid 351191561)
38. L.M. Bimbo, E. Makila, T. Laaksonen, V.P. Lehto, J. Salonen, J. Hirvonen, H.A. Santos, Drug permeation across intestinal epithelial cells using porous silicon nanoparticles, Biomaterials 32 (2011) 2625-2633.
39. F. Wang, H. Hui, T.J. Barnes, C. Barnett, C.A. Prestidge, Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs, Mol. Pharm. 7 (2010) 227-236.
40. M. Kovalainen, J. Monkare, M. Kaasalainen, J. Riikonen, V.P. Lehto, J. Salonen, K.H. Herzig, K. Jarvinen, Development of porous silicon nanocarriers for parenteral peptide delivery, Mol. Pharm. 10 (2013) 353-359.
41. H.A. Santos, J. Riikonen, J. Salonen, E. Makila, T. Heikkila, T. Laaksonen, L. Peltonen, V.P. Lehto, J. Hirvonen, In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size, Acta Biomater. 6 (2010) 2721-2731.
42. M. Kilpelainen, J. Riikonen, M.A. Vlasova, A. Huotari, V.P. Lehto, J. Salonen, K.H. Herzig, K. Jarvinen, In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles, J. Control. Release 137 (2009) 166-170.
43. J. Salonen, L. Laitinen, A.M. Kaukonen, J. Tuura, M. Bjorkqvist, T. Heikkila, K. Vaha-Heikkila, J. Hirvonen, V.P. Lehto, Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs, J. Control. Release 108 (2005) 362-374. (Pubitemid 41608668)
44. S. Brunauer, P.H. Emmett, E. Teller, Adsorption of gases in multimolecular layers, J. Am. Chem. Soc. 60 (1938) 309-319.
45. S.M. Kelly, T.J. Jess, N.C. Price, How to study proteins by circular dichroism, Bba-Proteins Proteom 1751 (2005) 119-139. (Pubitemid 41112231)
46. M. Del Arco, E. Cebadera, S. Gutierrez, C Martin, M.J. Montero, V. Rives, J. Rocha, MA Sevilla, Mg, Al layered double hydroxides with intercalated indomethacin: synthesis, characterization, and pharmacological study, J. Pharm. Sci. 93 (2004) 1649-1658. (Pubitemid 38725035)
47. K.L. Jarvis, T.J. Barnes, CA. Prestidge, Thermal oxidation for controlling protein interactions with porous silicon, Langmuir 26 (2010) 14316-14322.
48. M. Kaasalainen, E. Makila, J. Riikonen, M. Kovalainen, K. Jarvinen, K.H. Herzig, V.P. Lehto, J. Salonen, Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations, Int. J. Pharm. 431 (2012) 230-236.
49. S. Somasundaram, S. Rafi, J. Hayllar, G. Sigthorsson, M. Jacob, A.B. Price, A Macpherson, T. Mahmod, D. Scott, J.M. Wrigglesworth, I. Bjarnason, Mitochondrial damage: a possible mechanism of the "topical," phase of NSAID induced injury to the rat intestine, Gut 41 (1997) 344-353. (Pubitemid 27428194)
50. T.J. Laaksonen, H.M. Laaksonen, J.T. Hirvonen, L Murtomaki, Cellular automata model for drug release from binary matrix and reservoir polymeric devices, Bio-materials 30 (2009) 1978-1987.
51. I. Lynch, A. Salvati, K.A. Dawson, Protein-nanoparticle interactions what does the cell see? Nat. Nanotechnol. 4 (2009) 546-547.
52. A.E. Nel, L Madler, D. Velegol, T. Xia, E.M.V. Hoek, P. Somasundaran, F. Klaessig, V. Castranova, M. Thompson, Understanding biophysicochemical interactions at the nano-bio interface, Nat. Mater. 8 (2009) 543-557.
53. A. Kumari, S.K. Yadav, Cellular interactions of therapeutically delivered nanoparticles, Expert Opin. Drug Deliv. 8 (2011) 141-151.
54. K. Saha, A. Bajaj, B. Duncan, V.M. Rotello, Beauty is skin deep: a surface monolayer perspective on nanoparticle interactions with cells and biomacromolecules, Small 7 (2011) 1903-1918.
55. A. Verma, F. Stellacci, Effect of surface properties on nanoparticle-cell interactions, Small 6 (2010) 12-21.
56. P. Artursson, K. Palm, K. Luthman, Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv. Drug Deliv. Rev. (2012).
57. B. Sarmento, F. Andrade, S.B. da Silva, F. Rodrigues, J. das Neves, D. Ferreira, Cell-based in vitro models for predicting drug permeability, Expert Opin. Drug Metab. 8 (2012) 607-621.
58. C. Hilgendorf, H. Spahn-Langguth, CG. Regardh, E. Lipka, G.L Amidon, P. Langguth, Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport, J. Pharm. Sci. 89 (2000) 63-75. (Pubitemid 30080155)
59. A.M. Kaukonen, L. Laitinen, J. Salonen, J. Tuura, T. Heikkila, T. Limnell, J. Hirvonen, V.P. Lehto, Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles, Eur. J. Pharm. Biopharm. 66 (2007) 348-356. (Pubitemid 46756223)
60. V. Kerleta, I. Andrlik, S. Braunmuller, T. Franke, M. Wirth, F. Gabor, Poloxamer 188 supplemented culture medium increases the vitality of Caco-2 cells after subcultivation and freeze/thaw cycles, Altex-Altern. Anim. Ex. 27 (2010) 191-197.
61. S.M. Fischer, M. Brandl, G. Fricker, Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers, Eur. J. Pharm. Biopharm. 79 (2011) 416-422.
62. C.B. Woitiski, B. Sarmento, RA Carvalho, R.J. Neufeld, F. Veiga, Facilitated nano-scale delivery of insulin across intestinal membrane models, Int. J. Pharm. 412 (2011) 123-131.
63. E. Walter, S. Janich, B.J. Roessler, J.M. Hilfinger, G.L. Amidon, HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro in vivo correlation with permeability data from rats and humans, J. Pharm. Sci. 85 (1996) 1070-1076. (Pubitemid 26338920)
64. R.C.R. Beck, A.R. Pohlmann, C Hoffmeister, M.R. Gallas, E. Collnot, U.F. Schaefer, S.S. Guterres, CM. Lehr, Dexamethasone-loaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers, Eur. J. Pharm Biopharm 67 (2007) 18-30. (Pubitemid 46991337)
65. P.S. Burton, RA Conradi, A.R. Hilgers, N.F.H. Ho, L.L. Maggiora, The relationship between peptide structure and transport across epithelial-cell monolayers, J. Control. Release 19 (1992) 87-97.
66. H. Gao, Y.N. Wang, Y.G. Fan, J.B. Ma, Synthesis of a biodegradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl) amino-6-deoxy)-beta-cyclodextrin and its properties as the new carrier of protein delivery system, J. Control. Release 107 (2005) 158-173. (Pubitemid 41253711)
67. DA Keire, P. Mannon, M. Kobayashi, J.H. Walsh, T.E. Solomon, J.R. Reeve, Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity, Am J. Physiol. Gastrointest Liver Physiol. 279 (2000) 126-131.